Do GLP-1 Medicines Cause Muscle Loss?

A falling number on the scale does not tell you exactly what you have lost. That is why headlines about muscle loss during GLP-1 treatment can be both worrying and confusing.

Some lean tissue can be lost as body weight falls. The important questions are how much, what the measurement actually represents, and whether your strength and everyday function are being protected.

It helps to separate three things often treated as interchangeable: weight, lean mass, and muscle.

What “lean mass” actually means

A body-composition scan divides the body into categories. In a DXA scan, lean soft tissue includes more than skeletal muscle; it also includes water and other nonfat soft tissues. Bone mineral is measured separately.

So a study reporting a reduction in lean mass has not directly measured the same percentage loss of muscle. Nor has it necessarily measured a loss of strength. Those are related questions that require different assessments. The SURMOUNT-1 body-composition study defines these measures and discusses their limitations.

This distinction matters when a dramatic headline turns a scan result into a prediction about what will happen to your body.

What one tirzepatide study found

In a substudy of SURMOUNT-1, researchers analyzed body-composition scans from 160 adults with obesity or overweight, without type 2 diabetes. They compared pooled tirzepatide doses with placebo over 72 weeks.

About three-quarters of the weight lost in the tirzepatide group was fat mass and about one-quarter was lean mass. The proportions were similar in the placebo group, although the tirzepatide group lost substantially more weight overall.

That does not mean participants lost one-quarter of their starting muscle. It describes how the lost weight was divided between measurement categories.

The study was funded by Eli Lilly, tirzepatide’s manufacturer. It involved a relatively small subset of the larger trial and did not directly test muscle strength. Its published correction fixes the units on a subgroup graph; the overall fat-versus-lean proportions above are reported in the study’s results.

These findings help explain what happened in that group. They cannot predict an individual’s muscle changes or establish that all GLP-1 medicines have identical effects.

Strength is part of the treatment conversation

The ability to carry groceries, rise from a chair, climb stairs, or move comfortably matters alongside weight. A smaller body is not the only goal.

The joint nutrition advisory on GLP-1 treatment recommends attention to food intake, resistance exercise, and physical function. Older adults and people who already have low strength or difficulty eating may need particular support.

This does not mean every person needs a scan or an expensive gym membership. It means your care team should hear about changes in what you can do. New difficulty with stairs or getting out of a chair is useful information, even if you are pleased with the scale.

Food and movement work together

When appetite drops, it can take planning to get enough food and protein. A pattern of skipping meals and relying on a few bites at dinner is worth discussing. Our guide to eating with a smaller appetite offers practical starting points.

Resistance exercise asks muscles to work against a load. Depending on your ability, that might involve bands, weights, machines, or modified body-weight movements. The CDC recommends muscle-strengthening activity on at least two days a week for adults, alongside aerobic activity; people with health limitations can adapt activity with professional guidance. CDC adult activity guidance.

There is no need to begin with an ambitious routine. Ask what is safe and realistic for your joints, balance, experience, and health. A physical therapist or qualified exercise professional can help when movement is difficult.

Neither a protein target nor an exercise program guarantees that no lean tissue will be lost. The purpose is to support strength and function while treatment is adjusted to your needs.

Bring changes in function to follow-up

If you feel progressively weaker, unusually exhausted, or unable to eat enough, tell your clinician. Do not assume that weakness proves muscle loss—or that it is an unavoidable price of treatment. Symptoms need their own assessment.

A useful follow-up conversation can include weight, eating, activity, and one or two everyday tasks that matter to you. “I can walk farther, but lifting the shopping bags has become harder” tells a clinician more than the scale alone.

You deserve a treatment plan that pays attention to the person moving through daily life, as well as the number being recorded.